Ligand Pharmaceuticals Enters into License Agreement with KSQ Therapeutics

Represented Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) in connection with an OmniAb platform license agreement with KSQ Therapeutics, Inc. for human antibody discovery using transgenic rodents and chickens. Pursuant to the agreement, Ligand is eligible to receive annual platform access payments, development and regulatory milestone payments and tiered royalties for each product incorporating an OmniAb antibody.

Ligand is a biopharmaceutical company that focuses on developing and/or acquiring technologies that help pharmaceutical companies in discovering and creating medicines. KSQ Therapeutics is a preclinical-stage biotech company that develops transformative medicines which pinpoint the optimal nodal targets of disease.